|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, we observed an inverse relationship between L1CAM and ER/PR/E-cadherin expression in all ECs.
|
20077528 |
2010 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gene expression of SRC-1, SRC-2, SRC-3, N-CoR, SMRT, ERalpha, and PR was measured in 26 samples of normal endometrium and 30 primary endometrial carcinomas using real-time RT-PCR.
|
14751175 |
2004 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, inhibition of AKT stabilizes the Progesterone Receptor B and augments progesterone response in endometrial cancer cells that have hyperactivated AKT.
|
22911820 |
2012 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
181 genes were significantly up- or down-regulated with increasing BMI in endometrioid EC (q-value<0.01), including LPL, IRS-1, IGFBP4, IGFBP7 and the progesterone receptor.
|
27288544 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
One of the most prevalent potential therapeutic targets for women with endometrioid endometrial cancer (EC) is the estrogen receptor (ER)/progesterone receptor (PR) pathway.
|
30616900 |
2019 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the +331G/A progesterone receptor gene (PgR) polymorphism with risk of endometrial cancer in Caucasian women: a meta-analysis.
|
25037596 |
2015 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relative overexpression of estrogen receptor (ER)-alpha exon 5 splicing variant, the disrupted synchronization of ER-beta and ER-alpha expressions, and the suppression of progesterone receptor (PR) form A expression as a transcriptional repressor might be related to metastatic potential of uterine endometrial cancers, leading to poor patient prognosis related to estrogen refractoriness.
|
11282273 |
2000 |
|
Endometrial Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B.
|
30443761 |
2019 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The silencing of MIG6 using siRNA eliminated the P4-mediated reduction of EC cell viability, indicating that MIG6 is an essential downstream component of PR-mediated growth suppression.
|
28516379 |
2017 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Aberrant methylation patterns were observed in the first exon of PR gene, and the methylation density is correlated with the differentiation of different types of endometrial cancer cells.
|
17556066 |
2007 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated the estrogen-like effects of tamoxifen on the acceleration of growth and increased progesterone receptor concentrations of human endometrial carcinomas grown in the nude mouse experimental model.
|
1733196 |
1992 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No UIE tumors exhibited MSI, and the tumors in these patients had a higher expression of p53 (p < 0.01), a lower expression of ER (p < 0.05) and PR (p < 0.05), and a higher frequency of DNA aneuploidy (p < 0.01) than the UCE tumors.
|
11603221 |
2001 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NUCB2 immunoreactivity was detected in 19 out of 87 (22%) of endometrial carcinoma cases examined, and positively correlated with Ki67 labeling index, while there was no significant correlation between NUCB2 and stage, histological grade, and progesterone receptor status.
|
26842712 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings provide empirical evidence that PGR rs1042838 and rs10895068 polymorphisms may be involved in the pathogenesis of endometrial cancer.
|
26881523 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this retrospective study was to explore the possible correlation in the EC microenvironment between master regulators of complex phenomena such as steroid responsiveness through estrogen receptor alpha (ERα) and progesterone receptor (PR), epithelial-to-mesenchymal transition (supported by SLUG transcription factor), hypoxia (with hypoxia inducible factor-1 alpha, HIF-1α), and obesity that has been recognized as a EC risk factor.
|
31220580 |
2019 |
|
Endometrial Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of 7 tag SNPs that were assessed, 2 polymorphisms in the 3' flanking region of the PGR gene, reference SNP identification number (rs) 11224561 (rs11224561) and rs471767, were associated with the risk of endometrial cancer.
|
19382201 |
2009 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The prediction model using serum CA125 and the immunohistochemical markers PR and Ki67 is useful to predict patients with a low risk of LNM and has the potential to provide valuable guidance to clinicians in the treatment of patients with endometrioid endometrial cancer.
|
27163153 |
2016 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the immunohistochemical expression of the estrogen receptor (ER) and progesterone receptor (PR), p14, p53, phosphatase and tensin homolog (PTEN), Ki67, in patients with endometrial hyperplasia (EH) with/without atypia versus endometrioid endometrial carcinoma type 1.
|
29250656 |
2017 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pathways including progesterone receptor, TGFβ, ETV5 and microRNAs are deeply related to the EMT process in EC.
|
22911547 |
2012 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A lentiviral-based shRNA knockdown approach was used to generate stable PGRMC1-intact and PGRMC1-deplete Ishikawa endometrial cancer cell lines that also lacked expression of the classical progesterone receptor (PGR).
|
25304370 |
2015 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of these studies was to reestablish high progesterone receptor isoform A and B gene expressions in such endometrial cancer cells and to examine the effects of progestin treatment on cell growth and metastatic potential after this transformation.
|
11303185 |
2001 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only one (4.2%) of 24 endocervical carcinomas was positive for both estrogen receptor and progesterone receptor, whereas 18 (75%) of 24 endometrial carcinomas were positive for estrogen receptor and 23 (95.8%) of 24 endometrial carcinomas were positive for progesterone receptor (p <0.001, chi2 test).
|
12170086 |
2002 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Progesterone receptor (PR) mRNA was upregulated in the Ishikawa endometrial cancer cell line.
|
14974442 |
2004 |
|
Endometrial Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status.
|
14719079 |
2004 |
|
Endometrial Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since local tissue degradation is also a feature of malignant tumors, our goal was to analyze the gene expression of interleukin-1alpha and other interleukin-1 family members and compare it with estrogen receptor alpha, estrogen receptor beta, and progesterone receptor mRNA expression in 27 endometrial carcinomas and 13 normal endometria.
|
12051868 |
2002 |